However, antibodies against PD-1, which block both PD-L1 and PD-L2, show no obvious clinical advantage than antibodies against PD-L1, indicating PD-L1 is the dominant ligand of PD-1 in human tumor microenvironment (2). This evidence concerns the gene PDCD1 and neoplasm.